The online version of this article (https://doi.org/10.1186/s12885-017-3979-9) contains supplementary material, which is available to authorized users.
Prostate cancer is the most commonly diagnosed cancer in north-American men. Few dietary or lifestyle interventions have been tested to prevent prostate cancer progression. Omega-3 fatty acid supplementation represents a promising intervention for prostate cancer patients. The aim of the study is to evaluate the effects of long-chain omega-3 polyunsaturated fatty acids (LCn3), more precisely eicosapentaenoic acid monoacylglyceride (MAG-EPA) supplementation, on prostate cancer proliferation, inflammation mediators and quality of life among men who will undergo radical prostatectomy.
We propose a phase IIb, randomized, double-blind placebo-controlled trial of MAG-EPA supplementation for 130 men who will undergo radical prostatectomy as treatment for a prostate cancer of Gleason score ≥ 7 in an academic cancer center in Quebec City. Participants will be randomized to 6 capsules of 625 mg of fish oil (MAG-EPA) per capsule containing 500 mg of EPA daily or to identically looking capsules of high oleic acid sunflower oil (HOSO) as placebo. The intervention begins 4 to 10 weeks prior to radical prostatectomy (baseline) and continues for one year after surgery. The primary endpoint is the proliferative index (Ki-67) measured in prostate cancer cells at radical prostatectomy. A secondary endpoint includes prostate tissue levels of inflammatory mediators (cytokines and proteins) at time of radical prostatectomy. Changes in blood levels of inflammatory mediators, relative to baseline levels, at time of radical prostatectomy and 12 months after radical prostatectomy will also be evaluated. Secondary endpoints also include important aspects of psychosocial functioning and quality of life such as depression, anxiety, sleep disturbances, fatigue, cognitive complaints and prostate cancer-specific quality of life domains. The changes in these outcomes, relative to baseline levels, will be evaluated at 3, 6, 9 and 12 months after radical prostatectomy.
The results from this trial will provide crucial information to clarify the role of omega-3 supplementation on prostate cancer proliferation, inflammation and quality of life.
ClinicalTrials.gov Identifier: NCT02333435. Registered on December 17, 2014. Last updated September 6, 2016.
Additional file 1: Table S1. Trial biospecimen collection. The table contains detailed information on samples with volumes collected and aliquot (DOCX 15 kb)12885_2017_3979_MOESM1_ESM.docx
Prostate Cancer Statistics. Canadian Cancer Society, 2017. (Accessed March 28 2017, at http://www.cancer.ca/en/cancer-information/cancer-type/prostate/statistics/?region=on.)
Aucoin M, Cooley K, Knee C, et al. Fish-derived Omega-3 fatty acids and prostate cancer: a systematic review. Integr Cancer Ther. 2016;
Serra-Majem L, Nissensohn M, Overby NC, Fekete K. Dietary methods and biomarkers of omega 3 fatty acids: a systematic review. Br J Nutr 2012;107 Suppl 2:S64–S76.
Crowe FL, Appleby PN, Travis RC, et al. Circulating fatty acids and prostate cancer risk: individual participant meta-analysis of prospective studies. J Natl Cancer Inst. 2014;106
Moreel X, Allaire J, Leger C, et al. Prostatic and dietary omega-3 fatty acids and prostate cancer progression during active surveillance. Cancer Prev Res (Phila). 2014;7:766–76. CrossRef
Nariculam J, Freeman A, Bott S, et al. Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors. Asian J Androl. 2009;11:109–18. CrossRefPubMed
Sulik M, Guzinska-Ustymowicz K. Expression of Ki-67 and PCNA as proliferating markers in prostate cancer. Rocz Akad Med Bialymst. 2002;47:262–9. PubMed
Kim SH, Park WS, Park BR, et al. PSCA, cox-2, and Ki-67 are independent, predictive markers of biochemical recurrence in clinically localized prostate cancer: a retrospective study. Asian J Androl. 2016;
Aronson WJ, Kobayashi N, Barnard RJ, et al. Phase II prospective randomized trial of a low-fat diet with fish oil supplementation in men undergoing radical prostatectomy. Cancer Prev Res (Phila). 2011;4:2062–71. CrossRef
Demark-Wahnefried W, Polascik TJ, George SL, et al. Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiol Biomark Prev. 2008;17:3577–87. CrossRef
Blok WL, Deslypere JP, Demacker PN, et al. Pro- and anti-inflammatory cytokines in healthy volunteers fed various doses of fish oil for 1 year. Eur J Clin Investig. 1997;27:1003–8. CrossRef
Hervouet S, Savard J, Simard S, et al. Psychological functioning associated with prostate cancer: cross-sectional comparison of patients treated with radiotherapy, brachytherapy, or surgery. J Pain Symptom Manag. 2005;30:474–84. CrossRef
Hoffmire CA, Block RC, Thevenet-Morrison K, van Wijngaarden E. Associations between omega-3 poly-unsaturated fatty acids from fish consumption and severity of depressive symptoms: an analysis of the 2005-2008 National Health and nutrition examination survey. Prostaglandins Leukot Essent Fatty Acids. 2012;86:155–60. CrossRefPubMedPubMedCentral
Monograph: Fish Oil. Health Canada; 2015.
Vigneault E, Savard J, Ivers H, et al. Validation of a French-Canadian Version of the Expanded Prostate Cancer Index Composite Instrument. Can Urol Ass J 2017;In Press.
Godin G, Shephard R. Godin Leisure-Time Exercise Questionnaire. Med Sci Sports Exerc. 1997;29:S36–S8.
O'Brien RG, Muller KE. Unified power analysis for t-tests through multivariate hypothesis. In: Edwards LK, editor. Applied analysis of variance in the behavioral sciences. New York: Marcel Dekker; 1993. p. 297–344.
Self SG, Mauritsen RH, Ohara J. Power calculations for the likelihood ratio tests in generalized linear models. Biometrics. 1992;48:31–9. CrossRef
Kirk R. Experimental design: procedures for the behavioral sciences. Pacific Grove, Calif: Brooks/Cole; 1995.
Institute of Medicine, Food and Nutrition Board. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids (macronutrients). Washington, DC: National Academy Press; 2005.
U.S. Department of Health and Human Services, U.S. Department of Agriculture. 2015–2020 dietary guidelines for Americans. 2015.
- Effects of concentrated long-chain omega-3 polyunsaturated fatty acid supplementation before radical prostatectomy on prostate cancer proliferation, inflammation, and quality of life: study protocol for a phase IIb, randomized, double-blind, placebo-controlled trial
- BioMed Central
Neu im Fachgebiet Onkologie
e.Med Kampagnen-Visual, Mail Icon II